BioNTech hopes its purchase of CureVac will help boost its research into cancer treatments
From
To
Germany's BioNTech is buying domestic rival CureVac for $1.25 billion, the companies said Thursday, bringing together two pharmaceutical firms…
No Link Between COVID Vaccine During Pregnancy And Birth Defects, Study Says
Children ages 5 - 11 are now authorized to receive a booster dose of Pfizer/BioNTech’s COVID-19 vaccine at least five months after completion …